IMPORTANT: The trial is approved for up to 19 more patients to have the same therapy.
The following correction was issued shortly after this story was reported:
Correction to Earlier Release From Jewish Hospital and University of Louisville[Outline] ... ... ... ...LOUISVILLE Ky. July 24 -- In today's announc...[RSS & Subscription]
http://www.bio-medicine.org/inc/biomed/medicine-technology.asp
http://feeds.bio-medicine.org/latest-medical-technology
Email Subscription: Get Latest Medical Technology delivered by emailDate:7/24/2009[Outline] [RSS & Subscription]
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- In today's announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. louisville researchers and physicians have performed the world's first phase-one FDA-approved clinical trial using "c-kit-positive" adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of louisville physicians at jewish hospital, in collaboration with Dr. Piero Anversa and his team at the Brigham and Women's hospital in Boston.
Following the press conference Roberto Bolli, jewish hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for Molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells."
This is a small, but distinct difference than the procedure performed last month in California.
We regret any misunderstanding or confusion.
SOURCE jewish hospital
Copyright?2009 PR Newswire.
Here is the original story that was published before the correction:
University Of Louisville Doctors Perform Stem Cell Procedure
Gabe Bullard July 25, 2009, 12:52 pm | Email this to a friend
From WFPL?s Stephanie Sanders
Doctors at Jewish Hospital have performed one of the first infusions of adult stem cells into a patient?s heart. 66-year-old Louisvillian Mike Jones is the recipient the new treatment.
Doctors from Jewish Hospital and the University of Louisville harvested a small portion of Jones?s heart in March. It was sent to a lab to cultivate already-existing stem cells from his own heart and grow them at a rapid rate. Those stem cells were injected back into Jones?s heart July 17th. Cardiothoracic surgeon Dr. Mark Slaughter says Jones was a great candidate for the test.
?He had several heart attacks, he had very poor heart function. Physically, he was very limited. In several years, most likely, his only option would be transplant or potentially a mechanical heart,? he says.
Researchers hope the injected stem cells will perform their natural function, but at a more rapid rate, and repair the damaged muscle in Jones?s heart.
The following correction was issued shortly after this story was reported:
Correction to Earlier Release From Jewish Hospital and University of Louisville[Outline] ... ... ... ...LOUISVILLE Ky. July 24 -- In today's announc...[RSS & Subscription]
http://www.bio-medicine.org/inc/biomed/medicine-technology.asp
http://feeds.bio-medicine.org/latest-medical-technology
Email Subscription: Get Latest Medical Technology delivered by emailDate:7/24/2009[Outline] [RSS & Subscription]
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- In today's announcement regarding the use of stem cells in the treatment of heart failure, we failed to make a critical distinction. louisville researchers and physicians have performed the world's first phase-one FDA-approved clinical trial using "c-kit-positive" adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of louisville physicians at jewish hospital, in collaboration with Dr. Piero Anversa and his team at the Brigham and Women's hospital in Boston.
Following the press conference Roberto Bolli, jewish hospital Heart and Lung Institute Distinguished Chair in Cardiology and Director of UofL's Institute for Molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference between what we have done and what another institute nationally has done is that we have injected a pure population of stem cells, the c-kit-positive cells. The other institution injected cardiosphere-derived cells, which are a mixture of primitive and partially differentiated cells, complicating the recognition of the actual therapeutic cell. Our study involves a specific, well-characterized population of undifferentiated cells: the c-kit-positive cardiac stem cells are self-renewing, clonogenic and multipotent, which are the fundamental properties of stem cells."
This is a small, but distinct difference than the procedure performed last month in California.
We regret any misunderstanding or confusion.
SOURCE jewish hospital
Copyright?2009 PR Newswire.
Here is the original story that was published before the correction:
University Of Louisville Doctors Perform Stem Cell Procedure
Gabe Bullard July 25, 2009, 12:52 pm | Email this to a friend
From WFPL?s Stephanie Sanders
Doctors at Jewish Hospital have performed one of the first infusions of adult stem cells into a patient?s heart. 66-year-old Louisvillian Mike Jones is the recipient the new treatment.
Doctors from Jewish Hospital and the University of Louisville harvested a small portion of Jones?s heart in March. It was sent to a lab to cultivate already-existing stem cells from his own heart and grow them at a rapid rate. Those stem cells were injected back into Jones?s heart July 17th. Cardiothoracic surgeon Dr. Mark Slaughter says Jones was a great candidate for the test.
?He had several heart attacks, he had very poor heart function. Physically, he was very limited. In several years, most likely, his only option would be transplant or potentially a mechanical heart,? he says.
Researchers hope the injected stem cells will perform their natural function, but at a more rapid rate, and repair the damaged muscle in Jones?s heart.